NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm. Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
WASHINGTON, April 4, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm. Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
Dr. Drago is a CMC and global regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles. She has significant global expertise in the development of small molecules, biologics, cell and gene therapies, and combination products in multiple rare and common disease areas, including ophthalmology, neurology, immunology, and oncology. According to Dr. Carl Peck, Manager of the NDA Partners' drug development practice, "Dr. Drago's expertise in global regulatory and product development has been highly valued by our clients, and her leadership as Partner in the firm will play a critical role as we expand the services and regulatory support that we offer our clients."
Dr. Drago formerly served as Associate Professor at George Washington University's School of Medicine. She currently serves as Adjunct Faculty for the University of California, San Francisco (UCSF), American Course on Drug Development and Regulatory Sciences (ACDRS), and the University of Basel, European Center of Pharmaceutical Medicine (ECPM). She serves on the Board of Directors of the Regulatory Affairs Professional Society (RAPS), the Regulatory Affairs Committee of the American Society of Gene and Cell Therapy (ASGCT), and the Executive Committee of ACDRS.
Dr. Drago received her PhD in Chemistry from the Swiss Federal Institute of Technology (ETH) in Zurich and MS in Chemistry from the University of Messina in Italy. She is a TOPRA Fellow (FTOPRA) and a Fellow of the Regulatory Affairs Professional Society (FRAPS). She has received several awards, including the TOPRA Award for Regulatory Excellence and the RAPS Community Leadership Award.
About NDA Partners
NDA Partners, a ProPharma company, is a life sciences management consulting and contract development organization focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, product development program design and management, expert consulting, functional teams, project-based solutions, and clinical trial design and management.
Contact
Eric Fish, Vice President & General Manager
Office: 540-738-2550
[email protected]
Media Contact
Eric Fish, NDA Partners, 540-738-2550, [email protected]
SOURCE NDA Partners
Share this article